Search
Search Results
##search.searchResults.foundPlural##
-
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
1801PDF: 1419HTML: 328 -
THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA
2262PDF: 710HTML: 1703 -
DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES
1088HTML: 311PDF: 725 -
ADVANCED HODGKIN LYMPHOMA: A NEW ERA OF THERAPY
1968PDF: 1262HTML: 3465 -
NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES
1670PDF: 660HTML: 657 -
TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS
2564PDF: 925HTML: 5478 -
TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity
1401PDF: 1093HTML: 130 -
AUTOLOGOUS STEM CELL TRANSPLANTATION FOR AGGRESSIVE LYMPHOMAS
2304PDF: 796HTML: 2081 -
HEMATOPOIETIC CELL TRANSPLANTATION FOR OLDER PATIENTS WITH MDS
1704PDF: 695HTML: 3088 -
CLONAL HEMATOPOIESIS: ROLE IN HEMATOLOGIC NON-HEMATOLOGIC MALIGNANCIES CLONAL HEMATOPOIESIS AND MALIGNANCIES
1412PDF: 754HTML: 639 -
EPIDEMIOLOGY OF THERAPY-RELATED MYELOID NEOPLASMS IN THE NORDIC COUNTRIES
2039PDF: 719HTML: 1587Figure 1: 132Table 1: 150 -
THERAPY-RELATED MYELOID NEOPLASM IN NON-HODGKIN LYMPHOMA SURVIVORS
2384PDF: 659HTML: 2252 -
TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT Advanced systemic mastocytosis and midostaurin
982PDF: 759HTML: 163 -
TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS
3943PDF: 1618HTML: 1081 -
DEFERASIROX: OVER A DECADE OF EXPERIENCE IN THALASSEMIA
2493PDF: 1473HTML: 202 -
SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML
3361PDF: 791HTML: 6674 -
WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE
6997PDF: 2306HTML: 1622Table 1.: 156Table 2.: 171Table 3.: 153Table 4.: 146 -
INCIDENCE OF ACUTE MYELOID LEUKEMIA AFTER BREAST CANCER
2990PDF: 855HTML: 2896 -
THERAPY-RELATED MYELOID NEOPLASMS: PREDISPOSITION AND CLONAL EVOLUTION T-AML predisposition
1072PDF: 680HTML: 91 -
MOLECULAR PATHOGENESIS OF SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA
2551PDF: 761HTML: 6422Untitled: 176Untitled: 143Untitled: 145Untitled: 155 -
BONE MARROW MICROENVIRONMENT INVOLVEMENT IN T-MN: FOCUS ON MESENCHYMAL STEM CELLS MESENCHYMAL STEM CELL IN T-MN
1410PDF: 832HTML: 118 -
ESCHERICHIA COLI: AN IMPORTANT PATHOGEN IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES
1646PDF: 654HTML: 2061Untitled: 142Untitled: 126Untitled: 128Untitled: 126Untitled: 128Untitled: 149Untitled: 144 -
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA OF THE ELDERLY: REVIEW OF THE LITERATURE AND PERSPECTIVES. Hematopoietic stem cell transplatation in the elderly fo Acute Myeloid Leukemia
1295PDF: 446HTML: 123 -
COMPARISON OF INFECTIOUS COMPLICATIONS IN PATIENTS RECEIVING HIGH-DOSE CYCLOPHOSPHAMIDE AS GVHD AFTER TRANSPLANTATION FROM A 9/10 HLA-MATCHED UNRELATED DONOR WITH STANDARD GVHD PROPHYLAXIS AFTER TRANSPLANT FROM A FULL MATCHING DONOR Infection With PTCy Versus Standard GvHD Prophylaxis
1176PDF: 1198HTML: 66 -
TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH AIDA BASED REGIMEN
3472PDF: 701HTML: 1806 -
THERAPY-RELATED MYELOID NEOPLASMS: CONSIDERATIONS FOR PATIENTS’ CLINICAL EVALUATION. Clinical Evaluation of T-AML
1378PDF: 727HTML: 128 -
EFFICACY OF VENETOCLAX COMBINED WITH AZACITIDINE IN ELDERLY PATIENTS WITH RELAPSED ACUTE MYELOID LEUKEMIA
1000PDF: 535Suppl. Files: 280Html: 104 -
Treating relapsed/refractory acute myeloid leukemia with chidamide, fludarabine, cytarabine and granulocyte-colony stimulating factor with subsequent bridging to myeloablative allogeneic hematopoietic stem cell transplantation Treating relapsed/refractory acute myeloid leukemia with chidamide, fludarabine, cytarabine and G-CSF
1527PDF: 501HTML: 213







